Thinking of joining a study?

Register your interest

NCT06183762 | RECRUITING | Advanced Lung Cancer


A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Sponsor:

Hunan Province Tumor Hospital

Information provided by (Responsible Party):

Long Zhang

Brief Summary:

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

Condition or disease

Advanced Lung Cancer

Intervention/treatment

No treatment is included in this protocol.

Study Type : OBSERVATIONAL
Estimated Enrollment : 200 participants
Official Title : Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
Actual Study Start Date : 2020-01-01
Estimated Primary Completion Date : 2024-12-31
Estimated Study Completion Date : 2025-06-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Patients must be ≥18 years of age.
  • 2. Provision of fully informed consent prior to any study specific procedures.
  • 3. Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
  • 4. Genetic variants of tumor tissue detected by NGS.
Exclusion Criteria
  • None.

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Location Details

NCT06183762


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

China, Hunan

Hunan Province Tumor Hospital

Changsha, Hunan, China,

Loading...